Chief Operating Officer & Chief Scientific Officer
Dr Mehdi Gasmi joined SparingVision in December 2021 as Chief Operating Officer and took on the additional role of Chief Scientific Officer in April 2023.
He oversees SparingVision’s operations, Chemistry, Manufacturing & Control (CMC), and R&D strategy, driving innovation while ensuring operational excellence and playing a key role in scaling the company’s gene therapy platform from discovery to commercialization.
Mehdi has extensive experience in the design and translational development of gene therapy drug, having previously served as a Board member and, prior to that, as President and Chief Scientific Officer at Adverum Biotechnologies where he led the company’s R&D and translational operations for AAV-based gene therapy products, specifically ADVM-022, a treatment for ocular VEGF-driven diseases. Prior to Adverum, he has held leadership positions at Genethon, Ceregene, Cell Genesys and Chiron as well as academic research roles developing HIV-based vectors for gene delivery at City of Hope and UC San Diego.
Mehdi Gasmi holds an MSc and PhD in Biochemistry from the Claude Bernard University, Lyon. He is based in Europe